Abstract:Siming Yu, 1, 2 Xinxin Lu, 2 Chunsheng Li, 2 Zehui Han, 2 Yue Li, 2 Xianlong Zhang, 3 Dandan Guo 2, 4 1 The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, People's Republic of China; 2 Heilongjiang University of Traditional Chinese Medicine, Harbin, China; 3 The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; 4 The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, People's Republic of China Correspondence: Dandan Guo, The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, People's Republic of China, Email Xianlong Zhang The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China, Email Diabetic kidney disease (DKD) is a significant complication of diabetes and a major cause of end-stage renal disease. Affecting around 40% of diabetic patients, DKD poses substantial economic burdens due to its prevalence worldwide. The primary clinical features of DKD include the leakage of proteins into the urine, altered glomerular filtration, and an increased risk of cardiovascular diseases. Current treatments focus on managing hypertension and hyperglycemia to slow the progression of DKD. These include the use of SGLT2 inhibitors to control blood sugar and ACE inhibitors to reduce blood pressure. Despite these measures, current treatments do not cure DKD and fail to address its underlying causes. Emerging research highlights mitochondrial dysfunction as a pivotal factor in DKD progression. The kidneys' high energy requirements make them particularly susceptible to disturbances in mitochondrial function. In DKD, mitochondrial damage leads to reduced energy production and increased oxidative stress, exacerbating tissue damage. Mitochondrial DNA (mtDNA) damage is a key aspect of this dysfunction, with studies suggesting that changes in mtDNA copy number can serve as biomarkers for the progression of the disease. Efforts to target mitochondrial dysfunction are gaining traction as a potential therapeutic strategy. This includes promoting mitochondrial health through pharmacological and lifestyle interventions aimed at enhancing mitochondrial function and reducing oxidative stress. Such approaches could lead to more effective treatments that directly address the DKD. Keywords: diabetic kidney disease, TFAM, mitochondrial dysfunction, mitochondrial DNA, oxidative stress Diabetic kidney disease (DKD) is a prevalent microvascular complication among diabetes patients and a primary cause of end-stage renal disease. 1 Epidemiological studies indicate that nearly 40% of individuals with diabetes are affected by DKD, with its prevalence remaining relatively stable. 2 However, due to the vast number of people with diabetic nephropathy worldwide, DKD has escalated into a significant public health issue, imposing substantial economic burdens on both society and healthcare systems. Clinical manifestations of DKD include the leakage of albumin, metabolites, and ions into the urine, alterations in glomerular filtration rate, and an increased risk of cardiovascular disease and stroke. 3 Current pharmacological strategies for managing DKD primarily target hypertension and hyperglycemia, aiming to slow disease progression. 4 Medications such as SGLT2 inhibitors are used to control blood glucose levels, while ACE inhibitors and angiotensin receptor blockers target the renin-angiotensin system. These medications lower glomerular pressure, dilate small renal efferent arterioles, and reduce albumin excretion, with the goal of slowing the progression of DKD and preventing cardiovascular complications. However, these treatments do not address the underlying causes of DKD. Lifestyle modifications, including weight management, reducing salt intake, regular exercise, and dietary changes, have also proven beneficial in managing DKD by lowering blood pressure and reducing proteinuria. Despite the comprehensive application of these interventions, current treatment approaches cannot completely halt or reverse the progression of DKD. Thus, there is a critical need for the development of more effective and targeted therapies to overcome the clinical limitations of existing DKD treatments. 4 To address the challenge posed by DKD, targeting mitochondrial dysfunction has recently emerged as a promising strategy to halt disease progression. Mitochondria are the primary organelles responsible for energy production in the kidneys, whether in a healthy state or during DKD. The substantial energy and oxygen requirements of the kidn -Abstract Truncated-

Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease

Investigation of the Mechanism Underlying Calcium Dobesilate-Mediated Improvement of Endothelial Dysfunction and Inflammation Caused by High Glucose

Fenofibrate Attenuates Fatty Acid-Induced Islet Β-Cell Dysfunction and Apoptosis Via Inhibiting the NF-κB/MIF Dependent Inflammatory Pathway.

PPAR-α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Dihydrolipoamide S-acetyltransferase activation alleviates diabetic kidney disease via AMPK-autophagy axis and mitochondrial protection

Alpha lipoamide inhibits diabetic kidney fibrosis via improving mitochondrial function and regulating RXRα expression and activation

9-LB: PDZK1 Inhibits Fatty Acid Uptake in Renal Tubular Epithelial Cell Through FATP2 to Ameliorate Diabetic Kidney Disease

#5453 LIPID NEPHROTOXICITY INDUCED BY HIF-1α ACTIVATION ACCELERATES INTERSTITIAL INJURY IN DIABETIC NEPHROPATHY

The Role of Akt2 in the Protective Effect of Fenofibrate against Diabetic Nephropathy

Lipin-1 Deficiency Deteriorates Defect of Fatty Acid Β-Oxidation and Lipid-Related Kidney Damage in Diabetic Kidney Disease.

Atgl gene deletion predisposes to proximal tubule damage by impairing the fatty acid metabolism

Loss of Farnesoid X receptor (FXR) accelerates dysregulated glucose and renal injury in db/db mice

Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy and High-Fat Diet-Induced Renal Lipotoxicity

<b>CPT1A Protects Podocytes from Lipotoxicity and Apoptosis In Vitro and Alleviates Diabetic Nephropathy In Vivo</b><b>The role of CPT1A in diabetic kidney disease</b>

TFAM and Mitochondrial Protection in Diabetic Kidney Disease

Fenofibrate attenuates renal lipotoxicity in uninephrectomized mice with high-fat diet-induced obesity

Lipophagy deficiency exacerbates ectopic lipid accumulation and tubular cells injury in diabetic nephropathy

CD36 deletion ameliorates diabetic kidney disease by restoring fatty acid oxidation and improving mitochondrial function

CPT1A Protects Podocytes from Lipotoxicity and Apoptosis In Vitro and Alleviates Diabetic Nephropathy In Vivo

Methyl Cinnamate (MC) Alleviates Free Fatty Acids (FFAs) Induced Lipid Accumulation Through the AMPK Pathway in HepG2 Cells